Trial Profile
Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary) ; Cytarabine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms COMMODORE
- Sponsors Astellas Pharma
- 16 Aug 2023 Planned End Date changed from 30 Nov 2025 to 31 Mar 2026.
- 16 Aug 2023 Planned primary completion date changed from 30 Nov 2025 to 29 Feb 2024.
- 23 Jul 2022 Planned primary completion date changed from 31 Jul 2022 to 31 Oct 2022.